An experimental vaccine for pancreatic cancer has shown encouraging results in a phase 2 clinical trial. Pancreatic cancer remains one of the hardest cancers to treat, and approaches that train the immune system to recognise tumour cells are an active area of research.
Larger phase 3 trials are needed to confirm the benefit before the vaccine could become a standard treatment.
Source: Medical News Today















